You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
天士力(600535.SH):T89預防及治療急性高原反應適應症美國FDA臨牀試驗收到相關會議紀要
格隆匯 08-04 16:08

格隆匯8月4日丨天士力(600535.SH)公佈,公司複方丹蔘滴丸(FDA臨牀研究申報代碼為T89)預防及治療急性高原反應適應症美國FDA(美國食品藥品監督管理局)Ⅲ期臨牀試驗於2021年開始受試者入組,詳見公司《關於T89預防及治療急性高原反應申請美國新藥上市臨牀試驗進展情況暨風險提示公吿》(公吿編號:臨2021-040號)。公司就臨牀試驗主要進展與FDA召開會議,並於近日收到相關會議紀要。

複方丹蔘滴丸是由公司獨家開發研製的一種現代創新複方中藥,用於治療冠心病心絞痛,及 2 型糖尿病引起的Ⅰ期(輕度)、Ⅱ期(中度)非增殖性糖尿病視網膜病變。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account